Posted by Tygobar > 2019-08-31 14:44 | Report Abuse
I do really want to see if everything is really fine out there totally and completely for now in 2019 year and that's really it. I do want to see some more feedback from reputable members and that's really it. Do not get it at all how to see all fine anyway with that biotech.
Posted by Lalis > 2019-10-19 15:22 | Report Abuse
IT's our technology of the future which can be done with various needs anyway. I am all for that matter for example. Can we go on with that or no ? Let me think a bit about that. I am not sure how I can prolong, but I want to invest in some.
No result.
1
CEO Morning Brief
2
CEO Morning Brief
US Services Activity Expands at Modest Pace for a Second Month
3
CEO Morning Brief
4
CEO Morning Brief
5
CEO Morning Brief
Ultra-rich Families Set to Control US$9.5 Tril by 2030, Says Deloitte
#
Stock
Score
Stock
Last
Change
Volume
Stock
Last
Change
Volume
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Posted by inthemoneystocks > 2014-04-07 12:35 | Report Abuse
One of the hottest stock sectors in 2013 was the bio-technology stocks. Leading bio-tech stocks such as Celgene Corp (CELG), Gilead Sciences Inc. (GILD), Vertex Pharmaceuticals Incorporated (VRTX), and Amgen Inc (AMGN) were some of the biggest winners last year. So far in 2014, this high growth industry group has been in correction mode. Many of the leading bio-tech stocks are now trading lower by 20.0 percent or more since the start of the new year. While it is safe to say that the bio-tech sector is severely oversold, this important industry group has not yet bottomed out. Traders and investors can expect minor bounces in the bio-tech stocks from current levels, but it is not a true bottom in the industry group just yet. Remember nothing in the stock market goes down or up in a straight line. One of the ways that traders and investors can play the entire bio-tech sector is to use and follow the iShares NASDAQ Biotechnology Index ETF (IBB). At this time, the IBB is signaling downside to the $202.00 level. This is an area where the institutional money will likely come back in and support the bio-tech stocks, until then the bounces in the sector are likely to be just small rallies from an oversold condition. Nicholas Santiago InTheMoneyStocks